I'm a healthcare professional interested in new drug approvals and educational content. First, please navigate directly to the 'Volume 48 - 2025, Issue 3 June' of the Australian Prescriber. In the 'NEW DRUGS' section, find 'Semaglutide' and state its new indication and its previous approval. Second, I'm looking to subscribe to the journal; please navigate directly to the 'Volume 42 - 2019, Issue 1 February' and identify the primary requirement to obtain a free subscription from the 'IF YOU PRESCRIBE SUBSCRIBE' section.
Navigate directly to 'https://australianprescriber.tg.org.au/issues/48/3/'. On the 'Volume 48 - 2025, Issue 3 June' page, locate the 'NEW DRUGS' section. Identify 'Semaglutide' and extract its new indication and its previous approval. Navigate directly to 'https://australianprescriber.tg.org.au/issues/42/1/'. On the 'Volume 42 - 2019, Issue 1 February' page, find the 'IF YOU PRESCRIBE SUBSCRIBE' section and identify the primary requirement for obtaining a free subscription. Synthesize all collected information into a concise answer.
The agent successfully navigates directly to 'Volume 48 - 2025, Issue 3 June'. The agent states that 'Semaglutide's' new indication is 'cardiovascular risk reduction in people who are overweight or have obesity without diabetes' and its previous approval was 'for type 2 diabetes'. The agent successfully navigates directly to 'Volume 42 - 2019, Issue 1 February'. The agent states that the primary requirement for a free subscription is to be a 'registered Australian healthcare professional'.